Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

PAHC vs KTWO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PAHC Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

PAHC Overall Winner 6-Pillar Tally: PAHC 6 – 0 KTWO Matrix Metrics: PAHC 8 – 2 KTWO

As of Nov 20, 2026, Phibro Animal Health Corporation Class A (PAHC) is the stronger overall head-to-head candidate over KTWO (KTWO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PAHC carries a Unified Composite Score of 65.9/100 (BUY) at $33.29 (10.0x Forward P/E, 12.7% operating margin), whereas KTWO carries 55.8/100 (HOLD) at $10.12 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: PAHC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile KTWO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 57.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PAHC vs KTWO
PAHC NASDAQ Head-to-Head Winner
Phibro Animal Health Corporation Class A
Pharmaceutical Preparations
$33.29
-2.32% 1D
Market Cap $1.4B
TTM Revenue $1.54B
Forward P/E 10.0x
Beta / 30D Vol 1.04β · 55% Vol
Unified Composite Score
65.9 / 100 BUY
Tech 70.0 Fund 65.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.3%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $36.30 · SMA50: $36.51
KTWO US Equity
KTWO
Institutional Equity
$10.12
-0.1% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.02β · 4% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 66.0 Fund 57.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.0 · SMA20: $9.96 · SMA50: $9.96

6-Pillar Scorecard Institutional Category Breakdown (PAHC 6 – 0 KTWO)

Columns: Metric · PAHC · KTWO
1. Valuation Multiples PAHC
Forward P/E 10.0x N/M
Trailing P/E 14.2x N/M
PEG Ratio 1.68x N/M
EV / Revenue 1.4x N/M
2. Growth & Scale PAHC
Revenue Growth (YoY) +6.3% N/A
Earnings Growth (YoY) +10.8% N/A
TTM Revenue (USD) $1.54B N/A
Market Cap $1.4B N/A
3. Profitability & Quality PAHC
Gross Margin 33.3% N/A
Operating Margin 12.7% N/A
Net Profit Margin 6.7% N/A
Return on Equity (ROE) 28.2% N/A
4. Balance Sheet & Cash Flow PAHC
Cash Generation (TTM) $22M N/A
Cash Flow Margin 1.4% N/A
Net Cash / Leverage $714M Net Debt (1.89x D/E) N/A ROE
Dividend Yield 1.35% None (0.00%)
5. Options & Positioning PAHC
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 70.3% (9th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat PAHC
OpEx & R&D Intensity 20.6% of Rev ($317M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PAHC (8) vs KTWO (2)
Institutional Metric PAHC KTWO Criterion Row Edge
Market Capitalization
Scale
$1.4B N/A Larger Scale PAHC
Trailing P/E Ratio
Valuation
14.2x N/M Lower Multiple PAHC
Forward P/E Ratio
Valuation
10.0x N/M Lower Multiple PAHC
Revenue Growth (YoY)
Growth
+6.3% N/A Higher Growth PAHC
Operating Margin (TTM)
Profitability
12.7% N/A Higher Margin PAHC
Net Profit Margin
Profitability
6.7% N/A Higher Margin PAHC
Return on Equity (ROE)
Capital Efficiency
28.2% N/A Higher ROE PAHC
52-Week Range Position
Momentum
16% ($28–$60) 97% ($10–$10) Stronger Trend KTWO
Beta / 30D Volatility
Risk Regime
1.04β · 55% Vol 0.02β · 4% Vol Lower Realized Risk KTWO
Unified Institutional Score
Composite Signal
65.9 / 100 (BUY) 55.8 / 100 (HOLD) Higher Composite PAHC
Trailing 12M Revenue (USD)
Operating Scale
$1.54B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
33.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.68x PEG · 1.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$22M ($714M Net Debt (1.89x D/E)) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KTWO +5.19 pp
PAHC: -4.99% · KTWO: +0.2%
3M Horizon PAHC +5.49 pp
PAHC: +7.2% · KTWO: +1.71%
6M Horizon KTWO +38.35 pp
PAHC: -35.82% · KTWO: +2.53%
1Y Horizon KTWO +38.35 pp
PAHC: -35.82% · KTWO: +2.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PAHC vs KTWO. Trailing 12-month operating profitability (PAHC 12.7% vs KTWO N/A) and valuation multiples (PAHC 10.0x vs KTWO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PAHC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.54B
Gross Margin33.3%
Op. Margin12.7%
ROE / Fwd P/E28.2% · 10.0x
KTWO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PAHC CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 70.3%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact PAHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KTWO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KTWO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PAHC Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.4B market capitalization and 12.7% operating margin.
OpEx & R&D Reinvestment 20.6% of Rev ($317M)
90D Engineering Disclosures 0 Published
KTWO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PAHC vs KTWO Key Questions & Quantitative Answers

As of Nov 20, 2026, Phibro Animal Health Corporation Class A (PAHC) is the stronger overall head-to-head candidate over KTWO (KTWO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PAHC carries a Unified Composite Score of 65.9/100 (BUY) at $33.29 (10.0x Forward P/E, 12.7% operating margin), whereas KTWO carries 55.8/100 (HOLD) at $10.12 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: PAHC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile KTWO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 57.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PAHC leads the Growth & Scale pillar: PAHC posts +6.3% YoY revenue growth and +10.8% YoY earnings growth on $1.54B TTM revenue (33.3% gross margin, 12.7% operating margin), compared with KTWO at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, PAHC generates $1.54B in USD-normalized revenue versus N/A for KTWO. In operating R&D and SG&A reinvestment, PAHC deploys 20.6% of Rev ($317M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KTWO.

PAHC screens cheaper on headline valuation multiples. PAHC trades at 10.0x Forward P/E, 14.2x Trailing P/E, 1.68x PEG, and 1.4x EV/Revenue (1.4% FCF margin), whereas KTWO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PAHC (28.2% ROE) versus KTWO (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, PAHC carries 70.3% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 55% Vol realized risk). By comparison, KTWO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.02β · 4% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.